title: Increase in Distant Stage Breast Cancer Incidence Rates in US Women Aged 25-49 Years, 2000-2011: The Stage Migration Hypothesis.
abstract: Background. Unexplained increases have been reported in incidence rates for breast cancer diagnosed at distant stage in younger U.S. women, using data from the Surveillance, Epidemiology and End Results (SEER) Program. Methods. This report focused on recent SEER trends (2000-2011) in age-standardized incidence rates of invasive breast cancer at ages 25-39 and 40-49 years and the hypothesis that stage migration may have resulted from advances in detecting distant metastases at diagnosis. Results. Increases in the rates for distant stage were roughly equal to decreases in the rates for the most advanced stage subgroups within regional stage; this was evident for estrogen receptor (ER) negative cancers, associated with poorer prognosis, but not for ER positive cancers. The 3-year relative survival rate increased over time for distant stage (especially in the ER positive subgroup) and regional stage but not for localized stage; these trends do not contradict the stage-migration hypothesis. Conclusions. Findings provide some support for stage migration as one explanation for the recent increase in incidence of distant stage breast cancer, but additional studies are needed using other databases.
authors: Private Practice, 241 Stonecrest Drive, Bristol, CT 06010, USA.
authors: Anthony P
authors: AP
authors: Polednak
references: JAMA. 2013 Feb 27;309(8):800-5
references: 23443443
references: Ann Oncol. 2008 Jul;19(7):1249-54
references: 18356138
references: Cancer. 2014 May 1;120(9):1290-314
references: 24343171
references: Cancer. 2011 May 15;117(10 ):2209-18
references: 21523735
references: Lancet Oncol. 2009 Jun;10 (6):606-14
references: 19482249
references: Clin Breast Cancer. 2003 Apr;4 Suppl 1:S55-63
references: 12756080
references: J Nucl Med. 2011 Oct;52(10 ):1526-34
references: 21880576
references: Semin Roentgenol. 2001 Jul;36(3):250-60
references: 11475071
references: Breast Cancer Res Treat. 2013 Nov;142(1):165-75
references: 24136668
references: BMC Cancer. 2012 Sep 28;12:435
references: 23020297
references: NCHS Data Brief. 2009 Aug;(21):1-8
references: 19674536
references: JAMA. 2013 Jun 19;309(23):2433
references: 23780447
references: N Engl J Med. 1985 Jun 20;312(25):1604-8
references: 4000199
references: J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S7-11
references: 16280118
references: BJOG. 2012 Dec;119(13):1572-82
references: 22947229
references: J Clin Oncol. 2012 May 10;30(14):1715-24
references: 22493340
references: J Natl Cancer Inst. 2011 Sep 21;103(18):1397-402
references: 21753181
references: Breast Cancer Res Treat. 2009 Sep;117(2):319-24
references: 19137426
references: J Natl Cancer Inst. 2012 Dec 19;104(24):1879-87
references: 23243198
references: J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
references: 21191117
references: Oncologist. 2013;18(4):e8-10
references: 23633451
references: JAMA. 2013 Jun 19;309(23):2435-6
references: 23780451
references: Arch Intern Med. 2008 Jul 28;168(14 ):1541-9
references: 18663166
references: Oncologist. 2011;16(8):1111-9
references: 21765193
references: Oncologist. 2012;17 (5):613-9
references: 22539550
references: PLoS One. 2014 Feb 28;9(2):e89172
references: 24586570
references: Ann Surg Oncol. 2013 Jan;20(1):102-10
references: 22878617